Advertisement

Topics

Cerecor Inc. Company Profile

08:03 EDT 23rd June 2018 | BioPortfolio

Driven by an innovative team of industry experts and leading scientists, Cerecor aspires to develop neuroscience drugs that will make a difference. We are committed to improving the lives of patients by addressing underserved segments of common diseases. We are focused exclusively on developing products that have human proof-of-concept in either the target or the molecule and possess biomarkers to guide development, and our clinical strategies employ the latest technologies to improve the likelihood of trial success. www.cerecor.com


News Articles [8 Associated News Articles listed on BioPortfolio]

Cerecor licenses several programs from Avadel

Cerecor Inc. is acquiring four of Avadel Pharmaceuticals PLC's marketed pediatric products.

Cerecor appoints Peter Greenleaf CEO

Cerecor Reports First Quarter 2018 Financial Results

BALTIMORE, May 11, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC) (“Cerecor” or the “Company”) today announced financial results for the first quarter of 2018. Net revenues for the fir...

Cerecor Buys Avadel\'s Pediatric Biz

Enter into license agreement to develop four LiquiTime or Micropump products

Cerecor to Acquire Avadel Pharmaceuticals' Pediatric Assets

BALTIMORE, MD--(Marketwired - February 12, 2018) - Cerecor, Inc. (NASDAQ: CERC) today announced it has entered into definitive agreements with Avadel U.S. Holdings, Inc., and certain of its subsidiari...

Cerecor Appoints Simon Pedder to its Board of Directors

BALTIMORE, MD--(Marketwired - April 09, 2018) - Cerecor, Inc. (NASDAQ: CERC), today announced that Simon C. Pedder, Ph.D. has been appointed to its Board of Directors. "We are delighted to welcome D...

Cerecor Appoints Peter Greenleaf as Chief Executive Officer

BALTIMORE, MD--(Marketwired - March 28, 2018) - Cerecor, Inc. (NASDAQ: CERC) today announced that its Board of Directors has appointed Peter Greenleaf as Chief Executive Officer. Mr. Greenleaf has se...

Cerecor Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017

BALTIMORE, MD--(Marketwired - April 02, 2018) - Cerecor Inc. (NASDAQ: CERC) today announced financial results for the fourth quarter and full year 2017. Net Revenues for the year ended 2017 were $27.8...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Cerecor Inc.

Driven by an innovative team of industry experts and leading scientists, Cerecor aspires to develop neuroscience drugs that will make a difference. We are committed to improving t...

More Information about "Cerecor Inc." on BioPortfolio

We have published hundreds of Cerecor Inc. news stories on BioPortfolio along with dozens of Cerecor Inc. Clinical Trials and PubMed Articles about Cerecor Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cerecor Inc. Companies in our database. You can also find out about relevant Cerecor Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record